Dx & Vx Co., Ltd. (KOSDAQ: 180400)

Market Cap	137.57B
Revenue (ttm)	45.34B
Net Income (ttm)	-27.90B
Shares Out	49.22M
EPS (ttm)	-923.80
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,313,703
Open	2,750.00
Previous Close	2,805.00
Day's Range	2,740.00 - 2,860.00
52-Week Range	1,639.00 - 7,270.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About Dx & Vx

Dx & Vx Co., Ltd. engages in the development and sale of bio-health care products and provides molecular genetic testing services primarily in South Korea. The company offers healthcare products, including Ofmom Carefree, oat fermented food, and biocleaners; diagnostic products, comprising CLIDEX, precision diagnostics, and in vitro diagnostic kit; health check services; CDx development services; medical data; and funeral home operation services. It provides bacterial vaccine for respiratory disease; macular degeneration drug; atopy dermatitis ...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2001
• Employees: 114
• Stock Exchange: KOSDAQ
• Ticker Symbol: 180400

Financial Performance

In 2023, Dx & Vx's revenue was 46.75 billion, an increase of 45.24% compared to the previous year's 32.18 billion. Losses were -27.48 billion, 3425.0% more than in 2022.